1093.HK

CSPC Pharmaceutical Group Ltd. (1093.HK) warned on Thursday that is net profit for the first nine months of this year fell about 16% compared with a year earlier.

It blamed the decline on falling revenue for its oncology and cardiovascular therapeutic drugs, which were down about 18% and 11%, respectively, year-on-year during the period. Those declines were partially offset by a 4% rise in revenue from its nervous system therapeutic drug sales. CSPC’s shares fell 13% to HK$5 in early Friday trade.

By A. Au

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

China bets big on stocks as consumers fret over pre-made food

Team China has pumped $550 billion into the country's two main stock markets, buying up nearly 5% of the market value of all listed companies. What's the thinking behind this strategy? And pre-made foods are in the spotlight after a popular blogger criticized a major restaurant chain for using such products. Why is this such a sensitive subject in China?